The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression
Open accessAbstract
PURPOSE: Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. METHODS: We used next-generation sequencing to study 214 patients with SMM. We performed whole-exome sequencing on 166 tumors, including 5 with serial samples, and deep targeted sequencing on 48 tumors. RESULTS: We observed that most of the genetic alterations necessary for progression have already been acquired by the diagnosis of SMM. Particularly, we found that alterations of the mitogen-activated protein kinase pathway ( KRAS and NRAS single nucleotide variants [SNVs]), the DNA repair pathway (deletion 17p, TP53, and ATM SNVs), and MYC (translocations or copy number variations) were all independent risk factors of progression after accounting for clinical risk staging. We validated these findings in an external SMM cohort by showing that patients who have any of these three features have a higher risk of progressing to MM. Moreover, APOBEC associated mutations were enriched in patients who progressed and were associated with a shorter time to progression in our cohort. CONCLUSION: SMM is a genetically mature entity whereby most driver genetic alterations have already occurred, which suggests the existence of a right-skewed model of genetic evolution from monoclonal gammopathy of undetermined significance to MM. We identified and externally validated genomic predictors of progression that could distinguish patients at high risk of progression to MM and, thus, improve on the precision of current clinical models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, RAS mutations, MYC translocations, APOBEC mutagenesis, and patterns of genomic complexity are the most commonly reported.8,9,11,69,76-83,84”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Either the decreased efficacy of the immune system or the selection of more aggressive and fit clones will eventually allow the MGUS/SMM to progress into MM.76,78,79,104”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, it is peculiar that these high-risk features are underrepresented among high-risk SMM compared to newly diagnosed MM.9,11,69,76-79”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [78]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationUno, H., Cai, T., Pencina, M. J., D'Agostino, R. B., & Wei, L. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4154 · Cited by 1,535
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
A monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J. M., Verma, P. S., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 568
Dispenzieri, A. A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D. R., Benson, J. T., Clark, R. J., Melton, L. J., Gertz, M. A., Kumar, S. K., et al. (2007) · Blood · doi:10.1182/blood-2007-08-108357 · Cited by 432
Self-citationRisk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Lakshman, A., Rajkumar, S. V., Buadi, F. K., Binder, M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Fonder, A. L., Hayman, S. R., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0077-4 · Cited by 299
Self-citationChromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma
Debes-Marun, C. S., Dewald, G., Bryant, S., Picken, E. B., Santana-Dávila, R., Gonzalez-Paz, N. C., Winkler, J. M., Kyle, R. A., Gertz, M. A., Witzig, T. E., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402797 · Cited by 227
Genomic patterns of progression in smoldering multiple myeloma
Bolli, N., Maura, F., Minvielle, S., Gloznik, D., Szalat, R., Fullam, A., Martincorena, I., Dawson, K. J., Samur, M. K., Zamora, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05058-y · Cited by 222
Self-citationDhodapkar, M. V., Sexton, R., Waheed, S., Usmani, S., Papanikolaou, X., Nair, B., Petty, N., Shaughnessy, J. D., Hoering, A., Crowley, J., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515239 · Cited by 192
MYC dysregulation in the progression of multiple myeloma
MMRF CoMMpass Network, Misund, K., Keane, N., Stein, C. K., Asmann, Y. W., Day, G., Welsh, S., Van Wier, S. A., Riggs, D. L., Ahmann, G., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0543-4 · Cited by 161
Self-citation
Cited by
Sorted by citations
Malard, F., Neri, P. E., Bahlis, N. J., Terpos, E., Moukalled, N. M., Hungria, V., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 387
Self-citationInternational Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Mateos, M.-V., Kumar, S., Dimopoulos, M. A., González-Calle, V., Kastritis, E., Hajek, R., De Larrea, C. F., Morgan, G. J., Merlini, G., Goldschmidt, H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00366-3 · Cited by 291
Self-citationGenomic profiling for clinical decision making in lymphoid neoplasms
de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A. J., Doǧan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., et al. (2022) · Blood · doi:10.1182/blood.2022015854 · Cited by 176
Self-citationChromosome 1q21 abnormalities in multiple myeloma
Schmidt, T. M., Fonseca, R., & Usmani, S. Z. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00474-8 · Cited by 154
Zhao, A., Zhou, H., Yang, J., Li, M., & Niu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01342-6 · Cited by 153
Roadmap to cure multiple myeloma
Rodríguez‐Otero, P., Paiva, B., & Miguel, J. F. S. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102284 · Cited by 146
Oben, B., Froyen, G., Maclachlan, K. H., Leongamornlert, D., Abascal, F., Zheng-Lin, B., Yellapantula, V., Derkach, A., Geerdens, E., Diamond, B. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22140-0 · Cited by 129
Boyle, E. M., Deshpande, S., Tytarenko, R., Ashby, C., Wang, Y., Bauer, M. A., Johnson, S. K., Wardell, C. P., Thanendrarajan, S., Zangari, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20524-2 · Cited by 128
Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine
Dutta, A. K., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Lightbody, E. D., Getz, G. A., & Ghobrial, I. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00593-y · Cited by 130
Self-citationGenome instability in multiple myeloma
Neuse, C. J., Lomas, O., Schliemann, C., Shen, Y. J., Manier, S., Bustoros, M. W., & Ghobrial, I. M. (2020) · Leukemia · doi:10.1038/s41375-020-0921-y · Cited by 134
Self-citationLarráyoz, M., Garcia-Barchino, M. J., Celay, J., Etxebeste, A., Jiménez, M., Pérez, C., Ordóñez, R., Cobaleda, C., Botta, C., Fresquet, V., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02178-3 · Cited by 93
Self-citationCowan, A., Ferrari, F., Freeman, S. S., Redd, R., El-Khoury, H., Perry, J., Patel, V., Kaur, P., Barr, H., Lee, D. J., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00386-6 · Cited by 86
Self-citationPlasma cell neoplasms and related entities—evolution in diagnosis and classification
Fend, F., Doǧan, A., & Cook, J. R. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03431-3 · Cited by 86
Boiarsky, R. P., Haradhvala, N. J., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Mouhieddine, T. H., Zavidij, O., Shih, M., Firer, D. T., Miller, M. L., El‐Khoury, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33944-z · Cited by 80
Self-citationImmune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Sklavenitis-Pistofidis, R., Aranha, M. P., Redd, R. A., Baginska, J., Haradhvala, N. J., Hallisey, M., Dutta, A. K., Savell, A., Varmeh, S., Heilpern-Mallory, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.017 · Cited by 70
Self-citationAccelerated single cell seeding in relapsed multiple myeloma
Landau, H. J., Yellapantula, V. D., Diamond, B. T., Rustad, E. H., Maclachlan, K. H., Gundem, G., Medina-Martinez, J. S., Ossa, J. A., Levine, M. F., Zhou, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17459-z · Cited by 72
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
Podar, K., & Leleu, X. P. (2021) · Cancers · doi:10.3390/cancers13205154 · Cited by 70
Mateos, M., Hernández, M.-T., Salvador, C., de la Rubia, J., de Arriba, F., López‐Corral, L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.07.030 · Cited by 59
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 61
Termini, R., Žihala, D., Terpos, E., Perez-Montaña, A., Jelínek, T., Raab, M., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1594 · Cited by 54
Musto, P., Engelhardt, M. M., Caers, J., Bolli, N., Kaiser, M., van de Donk, N. W. C. J., Terpos, E., Broijl, A., de Larrea, C. F., Gay, F., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278519 · Cited by 51
Self-citationMechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
Botta, C., Mendicino, F., Martino, E. A., Vigna, E., Ronchetti, D., Correale, P., Morabito, F., Neri, A., & Gentile, M. (2021) · Cancers · doi:10.3390/cancers13133213 · Cited by 51
New Biological Therapies for Multiple Myeloma
Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 47
Rees, M. J., & Kumar, S. K. (2024) · American Journal of Hematology · doi:10.1002/ajh.27327 · Cited by 48
Self-citationHe, X., Ma, J., Xue, Y., Yang, X., Wang, P., Zhang, L., Li, N., & Shi, Z. (2024) · Current Genomics · doi:10.2174/0113892029313473240919105819 · Cited by 44
Yu, T., Chaganty, B., Lin, L., Xing, L., Ramakrishnan, B., Wen, K., Hsieh, P. A., Wollacott, A., Viswanathan, K., Adari, H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00378-z · Cited by 43
Self-citationDutta, A. K., Alberge, J.-B., Lightbody, E. D., Boehner, C. J., Dunford, A., Sklavenitis-Pistofidis, R., Mouhieddine, T. H., Cowan, A. N., Su, N. K., Horowitz, E. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0482 · Cited by 41
Self-citationLudwig, H., Kainz, S., Schreder, M., Zojer, N., & Hinke, A. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101910 · Cited by 41
Defining precancer: a grand challenge for the cancer community
Faupel‐Badger, J. M., Kohaar, I., Bahl, M., Chan, A. T., Campbell, J. D., Li, J., Marzo, A. M. D., Maitra, A., Merrick, D. T., Hawk, E. T., et al. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00744-0 · Cited by 46
Self-citationRustad, E. H., Nadeu, F., Angelopoulos, N., Ziccheddu, B., Bolli, N., Puente, X. S., Campo, E., Landgren, O., & Maura, F. (2021) · Communications Biology · doi:10.1038/s42003-021-01938-0 · Cited by 42
Genome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 43
Chromothripsis as a pathogenic driver of multiple myeloma
Maura, F., Boyle, E. M., Rustad, E. H., Ashby, C., Kaminetzky, D., Bruno, B., Braunstein, M. J., Bauer, M., Blaney, P., Wang, Y., et al. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.04.014 · Cited by 39
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile
Bruinink, D. H. O., Kuiper, R., van Duin, M., Cupedo, T., van der Velden, V. H. J., Hoogenboezem, R. M., van der Holt, B., Beverloo, H. B., Valent, E. T., Vermeulen, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01217 · Cited by 37
Self-citationBustoros, M., Anand, S., Sklavenitis-Pistofidis, R., Redd, R., Boyle, E. M., Zhitomirsky, B., Dunford, A. J., Tai, Y.-T., Chavda, S. J., Boehner, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30694-w · Cited by 35
Self-citationMonitoring treatment response and disease progression in myeloma with circulating cell‐free DNA
Deshpande, S., Tytarenko, R. G., Wang, Y., Boyle, E. M., Ashby, C., Schinke, C., Thanendrarajan, S., Zangari, M., Zhan, F., Davies, F. E., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13541 · Cited by 37
Neri, P. E., Barwick, B. G., Jung, D., Patton, J. C., Maity, R., Tagoug, I., Stein, C. K., Tilmont, R., Leblay, N., Ahn, S., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0061 · Cited by 35
Self-citationGenomic landscape of multiple myeloma and its precursor conditions
Alberge, J.-B., Dutta, A. K., Poletti, A., Coorens, T. H. H., Lightbody, E. D., Toenges, R., Loinaz, X., Wallin, S., Dunford, A., Priebe, O., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02196-0 · Cited by 32
Self-citationNew horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 34
Self-citationLin, J., Wang, Z., Hong, Q., Zhang, P., Zhang, Z., He, L., Wang, Q., Shang, L., Wang, L.-J., Sun, Y., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.28217 · Cited by 32
Burgos, L., Tamariz‐Amador, L., Puig, N., Cedena, M., Guerrero, C., Jelı́nek, T., Johnson, S., Milani, P., Cordón, L., Pérez, J. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01916 · Cited by 32
Croucher, D. C., Richards, L. M., Tsofack, S. P., Waller, D. D., Li, Z., Wei, E. N., Huang, X. F., Chesi, M., Bergsagel, P. L., Sébag, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26598-w · Cited by 30
Self-citationHow I approach smoldering multiple myeloma
Vaxman, I., & Gertz, M. A. (2022) · Blood · doi:10.1182/blood.2021011670 · Cited by 28
Wiedmeier, J. E., & Bergsagel, P. L. (2022) · Life · doi:10.3390/life12060812 · Cited by 30
Self-citationVisram, A., Rajkumar, S. V., Kapoor, P., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., Kourelis, T., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00569-2 · Cited by 27
Self-citationLandgren, O. (2021) · Hematology · doi:10.1182/hematology.2021000303 · Cited by 30
Maura, F., Landgren, O., & Morgan, G. J. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1395 · Cited by 28
Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic Implications
Salomon‐Perzyński, A., Jamroziak, K., & Głodkowska‐Mrówka, E. (2021) · Diagnostics · doi:10.3390/diagnostics11091534 · Cited by 26
Sudha, P., Ahsan, A., Ashby, C., Kausar, T., Khera, A., Kazeroun, M. H., Hsu, C.-C., Wang, L., Fitzsimons, E., Salminen, O., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3695 · Cited by 28
Self-citationUnderstanding DNA Damage Response and DNA Repair in Multiple Myeloma
Petrilla, C., Galloway, J., Kudalkar, R., Ismael, A., & Cottini, F. (2023) · Cancers · doi:10.3390/cancers15164155 · Cited by 24
A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
Vià, M. D., Ziccheddu, B., Maeda, A., Bagnoli, F., Perrone, G., & Bolli, N. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000502 · Cited by 27
Zhang, J., Liu, X., Zhou, W., Lu, S., Wu, C., Wu, Z., Liu, R., Li, X., Wu, J., Liu, Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.654517 · Cited by 23
Allegra, A., Cancemi, G., Mirabile, G., Tonacci, A., Musolino, C., & Gangemi, S. (2022) · Cancers · doi:10.3390/cancers14174136 · Cited by 27
The Molecular Pathogenesis of Multiple Myeloma
Bolli, N., Martinelli, G., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.9054 · Cited by 22
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies
Visram, A., Cook, J., & Warsame, R. M. (2021) · Hematology · doi:10.1182/hematology.2021000304 · Cited by 26
Mouhieddine, T. H., Nzerem, C., Redd, R. A., Dunford, A. J., Leventhal, M. J., Sklavenitis‐Pistofidis, R., Tahri, S., El‐Khoury, H., Steensma, D. P., Ebert, B. L., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0093 · Cited by 22
Self-citationBonello, F., Cani, L., & D’Agostino, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830922 · Cited by 21
Nadeem, O., Aranha, M. P., Redd, R., Timonian, M., Magidson, S., Lightbody, E. D., Alberge, J.-B., Bertamini, L., Dutta, A. K., El-Khoury, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55308-5 · Cited by 20
Self-citationGenomics define malignant transformation in myeloma precursor conditions
Maura, F., Bergsagel, P. L., Ziccheddu, B., Kumar, S., Maclachlan, K., Derkach, A., Garces, J.-J., Firestone, R., Braggio, E., Asmann, Y., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01733 · Cited by 18
Self-citationZeissig, M. N., Zannettino, A. C. W., & Vandyke, K. (2020) · Cancers · doi:10.3390/cancers12123643 · Cited by 19
Yang, F., Ni, B., Lian, Q., Qiu, X., He, Y., Zhang, Q., Zou, X., He, F., & Chen, W. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1066410 · Cited by 17
Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma
Kazandjian, D., Diamond, B., Papadimitriou, M., Hill, E., Sklavenitis-Pistofidis, R., Ziccheddu, B., Blaney, P., Chojnacka, M., Durante, M., Maclachlan, K., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0210 · Cited by 16
Self-citationSaldarriaga, M. M., Darwiche, W., Jayabalan, D. S., Monge, J., Rosenbaum, C. A., Pearse, R. N., Niesvizky, R., & Bustoros, M. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1020011 · Cited by 16
Self-citationKastritis, E., Solia, E., Malandrakis, P., Theodorakakou, F., Ntanasis‐Stathopoulos, I., Kanellias, N., Fotiou, D., Migkou, M., Eleutherakis‐Papaiakovou, E., Spiliopoulou, V., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016083 · Cited by 16
Self-citationPositive selection as the unifying force for clonal evolution in multiple myeloma
Diamond, B. T., Yellapantula, V. D., Rustad, E. H., Maclachlan, K. H., Mayerhoefer, M. E., Kaiser, M., Morgan, G. J., Landgren, O., & Maura, F. (2021) · Leukemia · doi:10.1038/s41375-021-01130-7 · Cited by 16
The consultant's guide to smoldering multiple myeloma
Þorsteinsdóttir, S., & Kristinsson, S. Y. (2022) · Hematology · doi:10.1182/hematology.2022000355 · Cited by 16
Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
Merz, M., Hu, Q., Merz, A. M. A., Wang, J., Hutson, N., Rondeau, C., Celotto, K., Belal, A., Alberico, R. A., Block, A. W., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007457 · Cited by 15
Self-citationSaade, C., & Ghobrial, I. M. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104268 · Cited by 15
Self-citationDeletion of 17p in cancers: Guilt by (p53) association
van Kampen, F., Clark, A., Soul, J., Kanhere, A., Glenn, M. A., Pettitt, A. R., Kalakonda, N., & Slupsky, J. R. (2025) · Oncogene · doi:10.1038/s41388-025-03300-8 · Cited by 15
Boyle, E. M., Blaney, P., Stoeckle, J. H., Wang, Y., Ghamlouch, H., Gagler, D. C., Braunstein, M. J., Williams, L. S., Tenenbaum, A., Siegel, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3209 · Cited by 15
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Maura, F., Kaddoura, M., Poos, A. M., Baughn, L. B., Ziccheddu, B., Bärtsch, M.-A., Cirrincione, A., Maclachlan, K., Chojnacka, M., Diamond, B., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02292-1 · Cited by 14
Self-citationPatterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma
Werly, A., Hampel, M., Hielscher, T., Zuern, K., Schmidt, S. K., Visram, A., Raab, M. S., Müller‐Tidow, C., Goldschmidt, H., & Mai, E. K. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01159-8 · Cited by 14
Ntanasis‐Stathopoulos, I., Filippatos, C., Malandrakis, P., Kastritis, E., Terpos, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01312-x · Cited by 14
Self-citationModeling the Bone Marrow Niche in Multiple Myeloma: From 2D Cultures to 3D Systems
Bottaro, A., Nasso, M. E., Stagno, F., Fazio, M., & Allegra, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136229 · Cited by 13
Samur, A. A., Corre, J., Talluri, S., Shah, P. S., Graffeuil, A., Rivera, J., Fan, Y., Dakiki, B., Szalat, R. E., Fulciniti, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00289 · Cited by 12
Self-citationSmoldering multiple myeloma: taking the narrow over the wide path?
Avet‐Loiseau, H., & Bahlis, N. J. (2024) · Blood · doi:10.1182/blood.2024023880 · Cited by 12
MYC alterations in multiple myeloma: Genetic insights and prognostic impact
Cristobal‐Vargas, S., Cuadrado, M., & Gutierrez, N. C. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101177 · Cited by 12
Genetic Predictors of Mortality in Patients with Multiple Myeloma
Hassan, H., & Szalat, R. E. (2021) · The Application of Clinical Genetics · doi:10.2147/tacg.s262866 · Cited by 12
High or low? Assessing disease risk in multiple myeloma
Schmidt, T. M. (2022) · Hematology · doi:10.1182/hematology.2022000347 · Cited by 12
Medina-Herrera, A., Vazquez, I., Cuenca, I., Rosa-Rosa, J. M., Ariceta, B., Jimenez, C., Fernandez-Mercado, M., Larrayoz, M. J., Gutierrez, N. C., Fernandez-Guijarro, M., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01053-3 · Cited by 11
Avigan, Z. M., Mitsiades, C. S., & Laganà, A. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.10.001 · Cited by 11
Sutanto, H., Sandra, D. Y., Safira, A., Adytia, G. J., Waitupu, A., & Romadhon, P. Z. (2025) · Medical Oncology · doi:10.1007/s12032-025-02807-0 · Cited by 12
Lightbody, E. D., Sklavenitis‐Pistofidis, R., Wu, T., Tsuji, J., Firer, D. T., Agius, M. P., Dutta, A. K., Barr, H., Kim, S., Alberge, J.-B., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01006-0 · Cited by 12
Self-citationSmoldering multiple myeloma – Past, present, and future
Mann, H., Katiyar, V., Varga, C., & Comenzo, R. L. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100869 · Cited by 12
Molecular Diagnostic Testing for Hematopoietic Neoplasms
Hergott, C. A., & Kim, A. S. (2022) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2022.04.005 · Cited by 11
Wu, E., Ni, J., Chen, X., Zhu, Z., Xu, H., Tao, L., & Xie, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894086 · Cited by 13
Terragna, C., Poletti, A., Solli, V., Martello, M., Zamagni, E., Pantani, L., Borsi, E., Vigliotta, I., Mazzocchetti, G., Armuzzi, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45000-z · Cited by 11
Bujarski, S. E., Goldwater, M., Regidor, B. S. S., Jew, S. K., Daniely, D., Swift, R. A., Eades, B., Emamy‐Sadr, M., Souther, E., Li, M., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13666 · Cited by 11
Smoldering Myeloma and the Art of War
Lonial, S., Dhodapkar, M. V., & Rajkumar, S. V. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00875 · Cited by 11
Hughes, D., Yong, K., Ramasamy, K., Stern, S., Boyle, E. M., Ashcroft, J., Basheer, F., Rabin, N. K., & Pratt, G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19333 · Cited by 10
Self-citationIsola, I., Brasó‐Maristany, F., Moreno, D. F., Mena, M.-P., Caldés, A. O., Paré, L., Rodríguez‐Lobato, L. G., Martín-Antonio, B., Cibeira, M. T., Bladé, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.792609 · Cited by 10
Risk Stratification and Treatment in Smoldering Multiple Myeloma
Lussier, T., Schoebe, N., & Mai, S. (2021) · Cells · doi:10.3390/cells11010130 · Cited by 11
Cao, Y.-J., Zheng, Y.-H., Li, Q., Zheng, J., Ma, L.-T., Zhao, C.-J., & Li, T. (2022) · Journal of Oncology · doi:10.1155/2022/4705654 · Cited by 10
Peat, T. J., Gaikwad, S. M., Dubois, W., Gyabaah-Kessie, N., Zhang, S., Gorjifard, S., Phyo, Z. H., Andres, M., Hughitt, V. K., Simpson, R. J., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216284 · Cited by 10
Intratumor microbiota: Occult participants in the microenvironment of multiple myeloma
Zhu, G., Jin, L., Shen, W., Zhao, M., & Liu, N. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188959 · Cited by 10
Gong, L., Qiu, L., & Hao, M. (2024) · Cancers · doi:10.3390/cancers16030498 · Cited by 10
What Is New in the Treatment of Smoldering Multiple Myeloma?
Bolli, N., Sgherza, N., Curci, P., Rizzi, R., Strafella, V., Delia, M., Gagliardi, V. P., Neri, A., Baldini, L., Albano, F., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030421 · Cited by 10
Selective Enhancer Gain-of-Function Deregulates MYC Expression in Multiple Myeloma
Rahmat, M., Clement, K., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Kodgule, R., Fulco, C. P., Heilpern-Mallory, D., Nilsson, K., Dorfman, D. M., Engreitz, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1440 · Cited by 10
Self-citationWhen a Monoclonal Gammopathy Is Not Multiple Myeloma
Derman, B. A., Castillo, J. J., Sarosiek, S., & Beksaç, M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349643 · Cited by 9
Evolution of Multiple Myeloma from a Genomic Perspective
Maura, F., Samur, M., & Munshi, N. (2026) · Blood · doi:10.1182/blood.2024026313 · Cited by 8
Self-citationVigliotta, I., Solli, V., Armuzzi, S., Martello, M., Poletti, A., Taurisano, B., Pistis, I., Mazzocchetti, G., Borsi, E., Pantani, L., et al. (2024) · Cancers · doi:10.3390/cancers16172929 · Cited by 8
Metadata
- Authors
- Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., Chavda, S. J., Boehner, C., Elagina, L., Neuse, C. J., Cha, J., Rahmat, M., Taylor-Weiner, A., Van Allen, E., Kumar, S., Kastritis, E., Leshchiner, I., Morgan, E. A., Laubach, J., Casneuf, T., Richardson, P., Munshi, N. C., Anderson, K. C., Trippa, L., Aguet, F., Stewart, C., Dimopoulos, M.-A., Yong, K., Bergsagel, P. L., Manier, S., Getz, G., & Ghobrial, I. M.
- Affiliations
- Broad Institute (US)
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- University College London (GB)
- Mayo Clinic (US)
- National and Kapodistrian University of Athens (GR)
- Brigham and Women's Hospital (US)
- Janssen (Belgium) (BE)
- Université de Lille (FR)
- Corresponding author
- Ghobrial, Irene M.
- ORCID
- Bustoros, Mark
- Park, Jihye
- Redd, Robert
- Zhitomirsky, Benny
- Dunford, Andrew J.
- Salem, Karma
- Tai, Yu-Tzu
- Anand, Shankara
- Mouhieddine, Tarek H.
- Chavda, Selina J.
- Boehner, Cody
- Neuse, Carl Jannes
- Cha, Justin
- Rahmat, Mahshid
- Taylor-Weiner, Amaro
- Kumar, Shaji
- Leshchiner, Ignaty
- Morgan, Elizabeth A.
- Laubach, Jacob
- Casneuf, Tineke
- Richardson, Paul
- Munshi, Nikhil C.
- Anderson, Kenneth C.
- Trippa, Lorenzo
- Aguet, François
- Stewart, Chip
- Dimopoulos, Meletios-Athanasios
- Yong, Kwee
- Bergsagel, P. Leif
- Manier, Salomon
- Getz, Gad
- Ghobrial, Irene M.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-07-20
- Volume
- 38
- Issue
- 21
- Pages
- 2380-2389
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC7367550
- OpenAlex
- W3027407129
- Cited by
- 187
- References
- 10
- Citations by year
- 2026: 14 · 2025: 29 · 2024: 35 · 2023: 26 · 2022: 32 · 2021: 35 · 2020: 16
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Multiple Myeloma Research Foundation
- Leukemia and Lymphoma Society
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Celgene
- European Hematology Association (TRTH177)
- Cancer Research UK
- National Institutes of Health
- Stand Up To Cancer
- Pharmacyclics
- National Human Genome Research Institute (T32HG002295)
- National Cancer Institute (R01CA195688, R01CA205954, R01CA168762, P50CA186781)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- smoldering multiple myeloma, progression to multiple myeloma, KRAS mutation, NRAS mutation, TP53 mutation, ATM mutations, 17p deletion, MYC translocation, MAPK signaling, DNA repair pathways, monoclonal gammopathy of undetermined significance, time to progression
- MeSH terms
- Smoldering Multiple Myeloma, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Risk Factors, Disease Progression, Genomics, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
